![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 50, 35393-35399, December 10, 1999
in NIH3T3 Cells Activates a Phospholipase A*
§,
,
,
,
From the
Centre for Biomembranes and Lipid
Enzymology, Department of Lipid Biochemistry, Institute of
Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The
Netherlands and ¶ Istituto de Richerche Farmacologiche
"Mario Negri," Consorzio Mario Negri Sud, Department of Cell
Biology and Oncology, 66030 Santa Maria Imbaro, Chieti, Italy
| |
ABSTRACT |
|---|
|
|
|---|
In order to investigate the cellular
function of the mammalian phosphatidylinositol transfer protein
(PI-TP
), NIH3T3 fibroblast cells were transfected with the cDNA
encoding mouse PI-TP
. Two stable cell lines, i.e. SPI6
and SPI8, were isolated, which showed a 2- and 3-fold increase,
respectively, in the level of PI-TP
. Overexpression of PI-TP
resulted in a decrease in the duration of the cell cycle from 21 h
for the wild type (nontransfected) NIH3T3 (wtNIH3T3) cells and
mock-transfected cells to 13-14 h for SPI6 and SPI8 cells. Analysis of
exponentially growing cultures by fluorescence-activated cell sorting
showed that a shorter G1 phase is mainly responsible for
this decrease. The saturation density of the cells increased from 0.20 × 105 cells/cm2 for wtNIH3T3 cells to
0.53 × 105 cells/cm2 for SPI6 and SPI8
cells. However, anchorage-dependent growth was maintained
as shown by the inability of the cells to grow in soft agar.
Upon equilibrium labeling of the cells with
myo-[3H] inositol, the relative
incorporation of radioactivity in the total inositol phosphate fraction
was 2-3-fold increased in SPI6 and SPI8 cells when compared with
wtNIH3T3 cells. A detailed analysis of the inositol metabolites showed
increased levels of glycerophosphoinositol, Ins(1)P, Ins(2)P, and
lysophosphatidylinositol (lyso-PtdIns) in SPI8 cells, whereas the
levels of phosphatidylinositol (PtdIns) and phosphatidylinositol
4,5-bisphosphate were the same as those in control cells. The addition
of PI-TP Phospholipid transfer proteins are proteins that are able to
transfer phospholipids between membranes in vitro. A major
phospholipid transfer protein in mammalian tissues is the
phosphatidylinositol transfer protein
(PI-TP)1 (1). Recently, two
isoforms of PI-TP have been identified (i.e. PI-TP PI-TP So far, very little is known about the precise cellular role of
mammalian PI-TP The above studies, using semi-intact cells and in vitro
systems, would indicate that PI-TP acts in different compartments of
the cell, in particular at the plasma membrane and at the Golgi membranes. Localization studies by indirect immunofluorescence and by
microinjection of fluorescently labeled purified PI-TP In order to gain further insight in the function and the mechanism of
action of PI-TP Materials
The pBluescript vector SK+ was from Stratagene (La Jolla, CA).
The anti-PI-TP antibodies were raised in rabbits against synthetic peptides representing the amino acid sequence of predicted epitopes in
rat brain PI-TP Methods
pSG5-PI-TP Cell Culture
All cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) containing 10% newborn calf serum (NCS) and buffered with
NaHCO3 (44 mM) in a 7.5% CO2
humidified atmosphere at 37 °C.
Transfections
wtNIH3T3 fibroblast cells were seeded 5 h prior to
transfection at a density of 1.3 × 104
cells/cm2. Cells were co-transfected with 30 µg of
pSG5-PI-TP Gel Electrophoresis and Immunoblotting
The PI-TP Growth Assay
Cells were seeded at a density of 5 × 104
cells/dish (9 cm2) in DMEM containing 10% NCS. Cell growth
was determined by counting the cells every day for 9 days (in
duplicate). The saturation density of the different cell lines was
determined by seeding 105 cells/dish (9 cm2),
and the number of cells was determined after 7 days (in triplicate). The medium was changed every 3 days in both assays.
To determine the ability of the different cell lines to grow in soft
agar, 2 × 104 cells were suspended in 0.3% agar in
DMEM containing 10% NCS and layered on 0.5% agar in the same medium.
Fresh medium was added every 5 days. The colony growth was determined
after 3 weeks.
Analysis of the Cell Cycle by Fluorescence-activated Cell
Sorting
Cells were resuspended in 10 mM EDTA in PBS and
washed once with PBS. The cells were fixed in PBS/methanol (3:7, v/v)
for 20 min at 4 °C. A 9-fold excess of PBS was added, and the
suspension was centrifuged for 5 min at 2500 rpm. The cell pellet was
resuspended in 100 µl of PBS containing RNase A (1 mg/ml). Propidium
iodide (50 µg/ml) was added, and the cells were incubated for 30 min at 37 °C. The samples were diluted 10-fold with PBS before analysis by fluorescence-activated cell sorting.
Labeling of the Cells: Extraction and Analysis of Inositol
Metabolites
Two methods were used to analyze the inositol metabolites. The
first method was used to obtain a quantitative preparation of the
water-soluble total inositol phosphate (IPn) fraction. The
second method was used to analyze the composition of the inositol phosphate fraction and of the inositol phospholipids.
Method 1--
The cells were grown in a six-well plate. 60-70%
confluent cell cultures were incubated for 48 h with 1 µCi of
myo-[3H]inositol in HEPES-buffered DF medium
without inositol, containing 2% dialyzed NCS. Cultures were washed
twice with PBS0 and scraped in 20 mM Tris buffer, pH 7.4, containing 0.25 M sucrose, 1 mM EDTA, 0.1%
Nonidet P-40, and 10 mM LiCl. The cells were sonicated for
1 min in a sonication bath (Branson 1200), and a small sample was
removed for protein determination. The cells were extracted by a
modified Bligh and Dyer method (45). Upon phase separation, the organic
phase was washed twice with MeOH/CHCl3, and the water phases were combined and loaded on a Seppak column (Waters
AccellTM Plus QMA Cartridges) Free
myo-[3H]inositol was eluted from the column by
water, and the total IPn fraction was eluted with 500 mM triethyl ammonium hydrogen carbonate buffer.
Radioactivity was determined by liquid scintillation counting. The
organic phase, including the protein layer, was acidified by the
addition of 0.03 N HCl and washed twice with
H2O/MeOH/0.03 N HCl. The inositol phospholipids
were separated by thin layer chromatography.
Method 2--
The cells were grown in a 12-well plate and
labeled as in method 1 except that 5 µCi of
myo-[3H]inositol was used. After labeling, the
cells were stimulated for 10 min with PDGF (20 ng/ml) or bombesin (10 nM). Prior to stimulation, 0.5 ml of DF medium without
inositol, containing 0.3% bovine serum albumin and 10 mM
LiCl, was added to the cells. After 10 min at 37 °C, the incubation
was continued for 15 min in the absence or presence of the growth
factors. Cultures were washed twice with PBS0 and harvested by scraping
in 1 ml of In Vitro Assay of PI-specific Phospholipase Activity
wtNIH3T3 cells were labeled to equilibrium with
myo-[3H]inositol (10 µCi) for 48 h in 5 ml of DF medium without inositol containing 2% dialyzed
NCS/50-cm2 dish. The cells were scraped in 1.5 ml of 50 mM HEPES, pH 7.4, containing 350 mM sucrose,
154 mM NaCl, 1 mM EDTA, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml phenylmethanesulfonyl fluoride and homogenized by 10 strokes in a Dounce homogenizer. The homogenate was
centrifuged at 400 rpm for 2 min in an Eppendorf centrifuge at 4 °C
to remove unbroken cells and cell debris, and 0.4 ml of the
supernatant, containing about 600,000 dpm in [3H]inositol
derivatives, was incubated for 30 min at 37 °C in the absence or
presence of Ca2+ (5 mM) and PI-TP Mouse NIH3T3 Fibroblast Cells Stably Transfected with the DNA
Encoding PI-TP
Mouse NIH3T3 fibroblast cells were co-transfected with both the
pSG5-PI-TP
The stable clones transfected with the control vector (pSV2-neo) are
denoted as OPIx (control vector, clone x), and the clones co-transfected with both pSG5-PI-TP Morphology, Growth Rate, Density Saturation, and
Anchorage-dependent Growth of the Transfected Cell
Lines--
Clones that expressed increased amounts of PI-TP
Analysis of the cellular DNA content in exponentially growing cell
cultures by fluorescence-activated cell sorting showed that in wtNIH3T3
cells and in OPI3 cells, respectively, 38 and 35% of the cells were in
the S phase/mitosis. For SPI6 cells and SPI8 cells, this percentage was
43 and 46%, respectively (Table I). From these values, and from the
duration of the full cell cycle, it was calculated that the
G1 phase is significantly shorter in SPI6 cells and SPI8
cells (7-8 h) than the G1 phase in wtNIH3T3 cells or in
OPI3 cells (13 h, Table I).
Confluent monolayers of wtNIH3T3 and SPI6/SPI8 cells were different. At
full confluency, wtNIH3T3 cultures shed dead cells, while SPI6/SPI8
monolayers started to curl up from the edges of the culture dish,
forming a "solid" piece of tissue after some time, indicating a
different interaction between the cells.
To investigate whether increased expression of PI-TP Incorporation of myo-[3H]Inositol--
In order to
investigate whether overexpression of PI-TP
TLC analysis of the inositol phospholipid fraction showed that the
relative incorporation of myo-[3H]inositol in
PtdIns, PtdIns(4)P or PtdIns(4,5)P2 was similar for
wtNIH3T3, SPI6, and SPI8 cells (data not shown).
Analysis of Inositol Metabolites in wtNIH3T3 and SPI8
Cells--
Since the water-soluble IPn fraction consists of a
great number of inositol-containing metabolites, it is very possible that the composition of the IPn fraction from the SPI6 and SPI8
cells is different from that of the growth factor-stimulated wtNIH3T3
cells. This possibility was investigated by analysis of the
water-soluble inositol metabolites by a high pressure liquid chromatograph connected to an on-line scintillation counter. The labeling and extraction procedures were adapted so as to increase the
incorporation of myo-[3H]inositol into the
metabolites and to optimize the recovery of lyso-PtdIns, which tends to
disappear from the organic phase by frequent wash steps. In agreement
with Fig. 2, the initial analyses of metabolites from SPI6 and SPI8
cells gave comparable results. We therefore restricted the detailed
analysis to the wtNIH3T3 and SPI8 cells.
As shown in Table II, the total
incorporation of myo-[3H]inositol in SPI8
cells was about 70% of that observed in wtNIH3T3 cells, whereas the
total amount of protein per well, reflecting the number of cells, was
twice as high. Despite this lower total incorporation, the absolute
amount of label in the water-soluble inositol phosphates from the SPI8
cells was about twice as high, while the absolute amount of label in
the inositol phospholipids was similar to that in the wtNIH3T3
cells.
The relative incorporation of myo-[3H]inositol
in the inositol phosphate and inositol phospholipid derivatives is
shown in Table III. The analysis of the
water-soluble inositol phosphates indicates that in SPI8 cells the
levels of Ins(1)P and Ins(2)P are significantly (p < 0.05) increased. There was also a 2-fold increase in the level of
GroPIns and a small change in the level of Ins(4)P. Low levels of
labeled Ins(1,4)P2 and Ins(1,4,5)P3 were also
detected, showing no significant difference between wtNIH3T3 and SPI8
cells. Analysis of the inositol phospholipids showed that in SPI8 cells
the relative incorporation of myo-[3H]inositol
in lyso-PtdIns was clearly increased (p = 0.06). In these cells, the incorporation in PtdIns(4)P was significantly decreased; no changes were observed in the relative labeling of PtdIns
and PtdIns(4,5)P2.
As shown in Fig. 2, the stimulation of the overexpressers with bombesin
(10 nM) did not result in an increased incorporation of
myo-[3H]inositol in the total IPn
fraction, in contrast to what was observed with the wild type cells. In
order to investigate whether the PLC-mediated degradation of
PtdIns(4,5)P2 is operative in the overexpressers, SPI8 and
wild type cells were stimulated with bombesin (10 nM) or
with PDGF (20 ng/ml). Analysis of the inositol phosphate fractions
showed that stimulation of the wtNIH3T3 cells mainly resulted in an
increased incorporation of myo-[3H]inositol in
Ins(1,4)P2 and Ins(4)P; there was no significant effect on
Ins(1)P and Ins(2)P (Table IV). However,
no effect was seen on the level of Ins(4)P or Ins(1,4)P2 in
SPI8 cells, indicating the loss of growth factor-stimulated
PtdIns(4,5)P2 degradation in these cells.
The Effect of PI-TP The cellular function of PI-TP As shown in Table I, enhanced levels of PI-TP Lyso-PtdIns has been shown to be a signaling molecule itself and could
therefore be responsible for the increased growth rate of SPI6 and SPI8
cells. The mechanism by which this molecule acts is not yet fully
clear. It has been proposed that lyso-PtdIns can either be released and
act by binding to a membrane receptor analogous to the reported
membrane receptor for lysophosphatidic acid or act intracellularly by
interacting with target proteins (29, 30, 47, 48). Furthermore,
lyso-PLA activity on lyso-PtdIns can produce GroPIns, which can itself
be phosphorylated to glycerophosphoinositol 4-phosphate, which has been
reported to be a novel intracellular messenger of the Ras pathway (28).
The increased levels of Ins(1)P and Ins(2)P in extracts of SPI8 cells
may represent an increased level of Ins(1:2 cyc)P in intact cells.
Increased levels of Ins(1:2 cyc)P have been correlated with a decreased
level or activity of the enzyme Ins-1:2-cyc-2 phosphohydrolase (49). An
increase in the level of Ins(1:2 cyc)P was thought to be correlated
with the loss of contact inhibition (50) and, therefore, could be the
reason for the higher cell density observed at confluency of SPI6 and
SPI8 cells. Whether the level or activity of Ins(1:2 cyc)P
2-phosphohydrolase actually is changed in SPI6 and SPI8 cells will a
the subject of future investigations. Upon activation of
PLA2, arachidonic acid may also be released, a precursor of the eicosanoids, which have been shown to participate in cell regulation, such as control of mitogenesis (25, 51).
The growth factors bombesin and PDGF were not able to activate the
PLC-mediated degradation of PtdIns(4,5)P2 in SPI6 and SPI8 cells. While in wtNIH3T3 cells, the Ins(4)P production is increased 4-10-fold by bombesin or PDGF, incubation of both SPI6 and SPI8 cells
with these growth factors had no effect on either the production of any
inositol phosphate or any of the phosphoinositides. The desensitization
of the PLC-dependent pathway could be explained by the SPI6
and SPI8 cells expressing either no receptors or impaired receptors for
bombesin or PDGF. On the other hand, it has been shown that an
increased level of lyso-PtdIns inhibits in vitro a
GTPase-activating protein (29). Furthermore, the antibiotic neomycin that is used to select successfully transfected cells could
also interfere with the PLC-mediated signal transduction pathway.
However, NIH3T3 cells that were transfected with cDNA encoding
PLC
to a total lysate of myo-[3H]inositol-labeled wtNIH3T3 cells
stimulated the formation of lyso-PtdIns. The addition of
Ca2+ further increased this formation. Based on these
observations, we propose that PI-TP
is involved in the production of
lyso-PtdIns by activating a phospholipase A acting on PtdIns. The
increased level of lyso-PtdIns that is produced in this reaction could
be responsible for the increased growth rate and the partial loss of
contact inhibition in SPI8 and SPI6 cells. The addition of growth
factors (platelet-derived growth factor, bombesin) to these overexpressers did not activate the phospholipase
C-dependent degradation of phosphatidylinositol
4,5-bisphosphate.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and
PI-TP
) that demonstrate differences in cellular localization and in
specific lipid transfer activity (2-5).
has been purified from both rat and bovine brain (6, 7).
Cloning of the cDNA encoding rat brain PI-TP
showed that the
protein consists of 271 amino acid residues (8). The subsequent
isolation of the cDNAs encoding mouse and human PI-TP
revealed a
high homology between the different mammalian PI-TPs (about 99% amino
acid sequence identity) (9, 10). Furthermore, the cross-reactivity of
the antibodies raised against bovine PI-TP
with a 35-kDa protein
from other animals (e.g. rat, mouse, chicken, frog, and
lizard) indicates an extensive conservation of the amino acid sequence
between species (11). An exception is PI-TP from yeast (i.e.
SEC14p) that has the same molecular weight as mammalian PI-TP and
comparable phospholipid transfer activities yet shows no homology in
the amino acid sequence (12-14).
. Since PI-TP
is able to transfer in
vitro PtdIns between membranes in exchange for
phosphatidylcholine, it was proposed that PI-TP
has a function in
the transfer of PtdIns from its site of synthesis in the endoplasmic
reticulum to other cellular membranes in order to maintain the level of PtdIns upon metabolism (15-17). PtdIns is a precursor molecule for
several intracellular (and possibly also extracellular) lipid messengers, the best characterized of which are 1,2-diacylglycerol and
inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) (18, 19). These
messengers are formed when PtdIns is phosphorylated by PtdIns 4-kinase
and phosphatidylinositol 4-phosphate 5-kinase to phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5)P2), which subsequently is
degraded by PLC. Other PtdIns derivatives of potential biological
significance include those formed in the PtdIns 3-kinase pathway (20,
21), the inositol polyphosphates (22), the cyclic inositolphosphates (23), the glycerophosphoinositols (24-28), and
lysophosphatidylinositol (lyso-PtdIns) (29-32). A number of recent
studies suggest a role of PI-TP
in the production of several of
these derivatives. Thomas et al. (33) showed that PI-TP
is an essential cytosolic factor to stimulate PLC
activity in
permeabilized HL60 cells. Furthermore, Cunningham et al.
(34) showed that PI-TP
promotes the synthesis of
PtdIns(4,5)P2. Recently, it was shown in permeabilized
human neutrophils that PI-TP
stimulates the formylmethionyl
leucylphenylanaline-dependent production of
phosphatidylinositol 3,4,5-trisphosphate in the presence of PtdIns
3-kinase
(35). Moreover, in permeabilized PC12 cells, PI-TP
was
found to be one of the three essential factors needed for the
ATP-dependent, Ca2+-regulated fusion of
secretory granules with the plasma membrane (36). An additional effect
on secretion was shown in permeabilized HL60 cells, where PI-TP
and
PI-TP
were able to restore GTP
S-stimulated protein secretion in
the presence of ADP-ribosylation factor (37). In a cell-free system
containing trans-Golgi membranes it was shown that PI-TP
(as well as PI-TP
) stimulates the formation of constitutive
secretory vesicles and immature secretory granules (38). These results
indicate that PI-TP has a function in intracellular membrane traffic
from the Golgi to the plasma membrane that may be linked to the
production of intracellular lipid messengers.
and PI-TP
into intact mammalian cells have shown that PI-TP
is mainly
localized in the nucleus and in cluster-like structures in the cytosol
and that PI-TP
is mainly associated with the Golgi membranes (3, 4,
39, 40). However, upon stimulation of the cells by different growth
factors (bombesin, PDGF) that stimulate the phospholipase
C-dependent degradation of PtdIns(4,5)P2, accumulation of PI-TP
near the plasma membrane was not observed. Thus, no correlation was found between the cellular localization of
PI-TP
and its proposed sites of action.
, we have established stable cell lines that
overexpress PI-TP
. In this paper, we show that overexpression of
PI-TP
in NIH3T3 cells affects the phenotype, the growth
characteristics, and the inositol lipid metabolism of these cells.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(39). Geneticin G418 and goat anti-rabbit IgG
conjugated with alkaline phosphatase were obtained from Sigma. Goat
anti-rabbit IgG conjugated with fluorescein isothiocyanate was from
Nordic Immunological Laboratories (Tilburg, The Netherlands). Nitrocellulose membranes were from Schleicher and Schuell. Agar-agar (Agar Noble) was obtained from Difco, RNase A from Roche Molecular Biochemicals, and myo-[2-3H]inositol from
Amersham Pharmacia Biotech.
Construct
The cDNA encoding mouse PI-TP
was isolated and cloned
into the pBluescript vector (9). The PI-TP
cDNA contains a
NcoI restriction site around the translational start codon
and an EcoRI and XhoI site downstream of the
translational stop codon. The NcoI-XhoI fragment
was isolated (including the EcoRI site) and ligated into the
cloning vector pUC21 (41) in the corresponding restriction sites in
order to introduce an extra EcoRI site upstream of the
PI-TP
cDNA. The resulting EcoRI fragment (containing
the complete coding cDNA) was cloned into the unique
EcoRI site of the pSG5 expression vector (42). A construct
was selected with the cDNA encoding PI-TP
in the sense
direction. This construct will be denoted as pSG5-PI-TP
. The
expression of PI-TP
will be regulated by the SV40 early promoter,
and polyadenylation will be provided by the SV40
poly(A)-adenylation signal (42).
and 10 µg of pSV2-neo (43) using a modified calcium
phosphate precipitation technique at a CO2 concentration of
7.5% (44). Fresh medium was added 20 h after transfection, and
the next day the cells were seeded in new flasks at a density of 2500 cells/10 cm2. After 24 h, neomycin (400 µg/ml
Geneticin G418) was added for the selection of neomycin-resistant
cells. Fresh medium containing neomycin was added every 4 days, and
resistant clones were identified after 2 or 3 weeks of growth.
content of several neomycin-resistant clones was
analyzed by immunoblotting with anti-PI-TP antibodies. Confluent cell
cultures were washed twice with PBS0 (phosphate-buffered saline without
Ca2+ and Mg2+) and removed from the dish by
incubation with 8 mM EGTA in PBS0 for 5 min at 37 °C.
The cells were centrifuged, and the pellet was stored at
20 °C. A
cell homogenate in 0.1 ml of SET buffer (10 mM Tris-HCl, pH
7.4, 1 mM EDTA, and 0.25 M sucrose) was
prepared in a Dounce homogenizer, followed by sonication (1 min at 50 watts). The homogenate was centrifuged for 10 min at 17,000 × g, and the A280 of the supernatant
was used to calculate the protein content. 17.5 µg of supernatant
protein was loaded on an SDS-polyacrylmide gel, and gel electrophoresis
was performed as described (39). The proteins were electrophoretically
transferred to a nitrocellulose sheet in a Multiphor II Nova Blot
electrophoretic transfer unit (Amersham Pharmacia Biotech) at room
temperature applying 1 mA/cm2 of gel for 2 h, and
PI-TP
was detected as described (39). Quantification of the PI-TP
levels on an immunoblot was performed by scanning with a Bio-Rad GS 700 imaging densitometer equipped with an integrating program, with known
PI-TP
concentrations as a standard.
20 °C MeOH. myo-[3H]Inositol,
the inositol phosphate fraction, and the inositol phospholipids were
extracted and analyzed as described previously (29, 30).
. Lipid
extraction and analysis were performed as described in method 2 (see above).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
--
The cDNA encoding mouse PI-TP
(9) was
cloned into the expression vector pSG5, and the vector with PI-TP
in
the sense orientation is denoted as pSG5-PI-TP
.
and pSV2-neo vectors or with only the pSV2-neo vector
(control) by a modified calcium phosphate precipitation technique (44).
Stable clones were selected by using the antibiotic Geneticin G418.
Several hundred positive neomycin-resistant clones appeared after 2 weeks. From these clones, we selected three stable clones transfected
with only the control pSV2-neo vector and 15 clones co-transfected with
both the pSG5-PI-TP
and the pSV2-neo vector.
and pSV2-neo are denoted as SPIx
(sense PI-TP
, clone x). The level of PI-TP
expression in these
clones was estimated by immunoblotting of the cytosolic fractions of
the cells. Two cell lines, SPI6 and SPI8, were selected because they
express an increased level of PI-TP
as compared with OPI3 and
wtNIH3T3 cells. Scanning of the immunostained PI-TP
bands indicated
that the transfected cell lines SPI6 and SPI8 show a 2- and 3-fold
increase in the PI-TP
level, respectively, as compared with the
wtNIH3T3 and OPI3 cells (Fig.
1A).

View larger version (53K):
[in a new window]
Fig. 1.
Analysis of the levels of
PI-TP
by Western blotting (A)
and the morphology of wtNIH3T3 cells, mock-transfected cells, and cells
that are transfected with cDNA encoding PI-TP
(B). A, 17.5 µg of protein of
the 100,000 × g supernatant of the cell lysates was
applied in each lane. Cell lysis, electrophoresis, and Western blotting
were performed as described under "Experimental Procedures." The
density of the PI-TP
bands was compared with the density of known
concentrations of PI-TP
. Gray bars, 10, 20, and 40 ng of purified recombinant mouse PI-TP
; white
bars, wtNIH3T3 (1), SPI8 (2), OPI3
(3), and SPI6 (4). B, morphology of
wtNIH3T3 (1), SPI6 (2), and SPI8 cells
(3).
displayed an altered morphology (Fig. 1B). These cells
(panels 2 and 3) were somewhat smaller
and rounder than wtNIH3T3 fibroblasts (panel 1).
The stably transfected cell lines displayed an increased growth rate
and a higher cell density at confluency (Table
I). The doubling time decreased from
21 h for wtNIH3T3 and OPI3 to 13-14 h for SPI6 and SPI8. In
addition, the maximal cell density when the cultures are fully
confluent increased from 0.20 × 105
cells/cm2 for wtNIH3T3 cells (or OPI3 cells, 0.16 × 105 cells/cm2) to 0.53 × 105
cells/cm2 for SPI6 and SPI8. Despite the difference in
expression of PI-TP
between SPI6 and SPI8 cells, no significant
difference in growth rate or saturation density was observed.
Growth characteristics of the cells that are transfected with the
cDNA encoding mouse P1-TP
led to
anchorage-independent growth of the cells, the capacity of the cells to
grow in soft agar was investigated. However, none of the cell lines
were able to form colonies in soft agar. Therefore, increased
expression of PI-TP
does not lead to a loss of contact inhibition or
to transformation.
affects the metabolism
of the inositol phospholipids, the SPI8/SPI6 cells and wtNIH3T3 cells
were labeled with myo-[3H]inositol, and the
relative incorporation in the inositol derivatives was determined as
described in method 1. After equilibrium labeling of the cells
(experimentally established by comparing various periods of labeling)
the 3H label in the total IPn fraction was
determined (Fig. 2). In wtNIH3T3 cells,
4.4% of the myo-[3H]inositol was incorporated
in the IPn fraction. The addition of LiCl had no significant
effect on the incorporation. However, incubation with bombesin, in the
presence of LiCl, led to a 2-3-fold increase in the incorporation of
myo-[3H]inositol in the IPn fraction
(Fig. 2). In the SPI6 and SPI8 cells, the percentage of incorporation
in the IPn fraction was 2-3-fold higher as compared with
wtNIH3T3 cells. Incubation with LiCl or with bombesin (in the presence
of LiCl) did not further increase the level of incorporation. This
indicates that the stimulation of the PLC-mediated degradation of
PtdIns(4,5)P2 is impaired in the cells overexpressing
PI-TP
.

View larger version (15K):
[in a new window]
Fig. 2.
Incorporation of
myo-[3H]inositol in the total
water-soluble inositol phosphate (IPn) fraction in wtNIH3T3,
SPI6, and SPI8 cells. Open bars, control
cells; gray bars, cells incubated with 10 mM LiCl; black bars, cells incubated
with 10 mM LiCl and 10 ng/ml bombesin.
Absolute and relative incorporation of myo-[3H]inositol in
inositol phosphates and inositol phospholipids in wtNIH3T3 and SPI8
cells
Relative incorporation of myo[3H]inositol into inositol
derivatives in wtNIH3T3 and SPI8 cells expressed as percentages of the
total cellular 3H label
Relative incorporation of myo-[3H]inositol in
Ins(1,4)P2, Ins(1)P, Ins(2)P, and Ins(4)P in wtNIH3T3 and SPI8
cells upon stimulation with bombesin (10 nM) or PDGF (20 ng/ml)
on the Formation of Lyso-PtdIns in
Vitro--
The increased level of lyso-PtdIns in the SPI8 cells
suggests the activation of a PLA1 and/or PLA2.
In order to investigate whether PI-TP
was able to stimulate the
formation of lyso-PtdIns in vitro, a homogenate of
myo-[3H]inositol-labeled wtNIH3T3 cells was
incubated with different amounts of this protein in the absence and
presence of Ca2+ (5 mM). Each incubation
contained about 0.1 µg of endogenous PI-TP
. As shown in Fig.
3, incubation with 0.5 µg of PI-TP
in the absence of Ca2+ led to a 2-fold increase in the
level of lyso-PtdIns. The formation of lyso-PtdIns was further enhanced
at a higher PI-TP
concentration (2.0 µg). In the presence of
Ca2+, the stimulatory effect of PI-TP
was more
pronounced. The increased levels of lyso-PtdIns were accompanied by a
significant decrease in the level of PtdIns (Fig. 3). Under the assay
conditions, there was no change in the absolute levels of
[3H]PtdIns(4)P and
[3H]PtdIns(4,5)P2. The level of lyso-PtdIns
in incubations with 0.1 µg of PI-TP
(the endogenous level)
reflected the level observed in intact cells (compare Fig. 3 and Table
III). These results indicate that wtNIH3T3 cells contain a
PLA1/PLA2 activity acting on PtdIns that can be
activated by PI-TP
in a Ca2+-sensitive fashion.

View larger version (12K):
[in a new window]
Fig. 3.
The formation of lyso-PtdIns in lysates of
myo-[3H]inositol-labeled wtNIH3T3 cells
incubated with PI-TP
in the absence
(open symbols) and presence
(closed symbols) of 5 mM
Ca2+. The 3H-labeled phosphoinositides
were separated by TLC, and the distribution of 3H label was
determined. The percentages of 3H label in PtdIns (
,
) and in lyso-PtdIns (
,
) are presented. These data are
representative for the results of three independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
has been extensively
investigated using permeabilized cells and cell-free systems (33, 36, 38, 46). From these studies it was inferred that PI-TP
is involved
in the synthesis of PtdIns(4,5)P2, possibly by delivering PtdIns to PtdIns 4-kinase. A more direct approach is to study the
PtdIns metabolism in cell lines in which the expression level of
PI-TP
is changed. In the present study we have established stable
mouse NIH3T3 fibroblast cell lines that express a 2-3-fold increase in
the levels of PI-TP
. These cells were chosen for the transfection
experiments because they have a well defined PtdIns metabolism, several
well known growth factor receptors, and a significant level of
endogenous PI-TP
.
lead to a dramatic
increase in the growth rate of the cells. The cause of the increased
growth rate can be manyfold. However, since PI-TP
is involved, we
have investigated the production of PtdIns metabolites. Two well known
PtdIns-derived mitogenic signals are Ins(1,4,5)P3 and
1,2-diacylglycerol, which are formed when a
PtdIns(4,5)P2-specific PLC is activated by binding of
growth factors to their receptors (18, 19). Another PtdIns derivative
with mitogenic activity is lyso-PtdIns that is produced by the
PLA2-dependent pathway (24, 25, 29, 30). In the
present study, we show that the incorporation of
myo-[3H]inositol in the water-soluble inositol
phosphate fraction was increased in the SPI8 cells when compared with
wtNIH3T3 cells. An increase of 3H-labeled inositol
phosphates was also observed in permeabilized PC12 cells upon the
addition of purified PI-TP
(33, 34, 37). However, in a number of
these studies the exact composition of the IPn fraction was not
established; an increased "IPn" fraction may include
Ins(1)P and Ins(2)P as well as glycerophosphoinositol (products of
PLA/lyso-PLA activation) and does not necessarily indicate that levels
of Ins(4)P (and hence PLC activity) have increased. Hence, detailed
analysis of the inositol phosphate fraction indicated that in SPI8
cells the levels of Ins(1)P and Ins(2)P were significantly increased,
whereas the levels of Ins(4)P, Ins(1,4)P2, and
Ins(1,4,5)P3 were similar to that in wtNIH3T3 cells. This
indicates that overexpression of PI-TP
in intact wtNIH3T3 cells has
no effect on PtdIns(4,5)P2-specific PLC. Rather, the
identified inositol phosphate derivatives are characteristic for the
degradation of PtdIns by PLA2 (24, 25, 27). In the latter
studies, it was shown that the lyso-PtdIns that is produced upon
activation of PLA2 can be degraded by a lysophospholipase to GroPIns. Alternatively, lyso-PtdIns can be degraded by a PLC to
Ins(1:2 cyc)P, which, due to the acidic extraction conditions used, may
be converted into Ins(1)P and Ins(2)P (23, 47). The activation of a
potentially PtdIns-specific PLA in SPI8 cells was confirmed by the
analysis of the inositol phospholipid fraction, showing that the level
of lyso-PtdIns was 2-3-fold increased as compared with control cells.
In line with the enhanced level of lyso-PtdIns, the level of GroPIns
was also increased in SPI8 cells. As for the other inositol
phospholipids in SPI8 cells, the relative incorporation of
myo-[3H]inositol was significantly decreased
in PtdIns(4)P, while there were no changes in PtdIns and
PtdIns(4,5)P2. Furthermore, the addition of purified
PI-TP
to a crude lysate of [3H]inositol-labeled
wtNIH3T3 cells induced a 2-3-fold increase in the level of lyso-PtdIns
most probably derived from PtdIns, since the level of
3H-labeled PtdIns decreased. No significant change was
observed in the relative labeling of PtdIns(4)P and
PtdIns(4,5)P2. These data strongly suggest that in cells
with an increased expression of PI-TP
, a potentially PtdIns-specific
PLA is constitutively activated. Based on former studies, the
activation of a PLA2 is most likely (25, 26). However,
activation of a PtdIns-specific PLA1 cannot as yet be
excluded. The procedures generally used to extract inositol
phospholipids may lead to a loss of the rather water-soluble
lyso-PtdIns. This may explain why the PLA-mediated signal transduction
pathway has not been detected in the semi-intact cells or in isolated
membrane systems upon the addition of PI-TP (33-37). Furthermore, and
as indicated above, the detailed analysis of inositol phosphates is
required to ascertain whether PLC and/or PLA is activated.
1 and selected by neomycin resistance were fully able to respond
to PDGF stimulation with increased IPn production
(52).2 The activation of
PLA2 and the simultaneous desensitization of PLC as
observed in the SPI6 and SPI8 cells has also been described for cells
transfected with ras or other cytoplasmic (mos,
raf) or membrane-associated (src, met,
trk) oncogenes but not with nuclear (myc,
fos) oncogenes (24). This may suggest that the intracellular
mechanisms of action of PI-TP
and the above oncogenes have certain
steps in common. It is also possible that PI-TP
is part of the
mechanism used by the oncogene proteins to activate PLA2.
On the other hand, activation of PLA2 has also been
observed during normal differentiation of neonatal liver cells (53), indicating that increased levels of GroPIns, lyso-PtdIns, and Ins(1)P
could also be associated with different stages of differentiation rather than being characteristic of the malignant transformation process.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Marcel van der Heyden for assistance with the transfection experiments and Dr. Hans van de Vuurst for help in the fluorescence-activated cell sorting analysis.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Netherlands Foundation for Chemical Research, the Netherlands Organization for Scientific Research, the Italian Association for Cancer Research, and the Italian Foundation for Cancer Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 31 30 2534668; Fax: 31 30 2522478; E-mail: g.t.snoek@chem.uu.nl.
2 S. G. Rhee, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PI-TP, phosphatidylinositol transfer protein;
PtdIns, phosphatidylinositol;
GroPIns, glycerophosphoinositol;
Ins(4)P, inositol 4-phosphate;
PtdIns(4)P, phosphatidylinositol 4- phosphate;
PtdIns(4, 5)P2, phosphatidylinositol 4,5-bisphosphate;
Ins(1, 4,5)P3, inositol 1,4,5-trisphosphate;
Ins(1, 4)P2, inositol 1,4-bisphosphate;
PLA, phospholipase
A;
PLC, phospholipase C;
PDGF, platelet-derived growth factor;
NCS, newborn calf serum;
DMEM, Dulbecco's modified Eagle's medium;
DF, DMEM supplemented with Ham's nutrient mixture F-12;
wtNIH3T3, wild
type (non-transfected) NIH3T3;
PBS, phosphate-buffered saline;
PBS0, PBS without Ca2+ and Mg2+;
GTP
S, guanosine
5'-3-O-(thio)triphosphate;
Ins(1:2 cyc)P, inositol
1:2-cyclic phosphate;
IPn, total inositol phosphate.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Wirtz, K. W. A. (1997) Biochem. J. 324, 353-360 |
| 2. |
Tanaka, S.,
and Hosaka, K.
(1994)
J. Biochem. (Tokyo)
115,
981-984 |
| 3. | De Vries, K. J., Heinrichs, A. A. J., Cunningham, E., Brunink, F., Westerman, J., Somerharju, P. J., Cockcroft, S., Wirtz, K. W. A., and Snoek, G. T. (1995) Biochem. J. 310, 643-649 |
| 4. | De Vries, K. J., Westerman, J., Bastiaens, P. I. H., Jovin, T. M., Wirtz, K. W. A., and Snoek, G. T. (1996) Exp. Cell Res. 227, 33-39[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Westerman, J.,
de Vries, K. J.,
Somerharju, P.,
Timmermans-Hereijgers, J. L. P. M.,
Snoek, G. T.,
and Wirtz, K. W. A.
(1995)
J. Biol. Chem.
270,
14263-14266 |
| 6. | Venuti, S. E., and Helmkamp, G. M., Jr. (1988) Biochim. Biophys. Acta 946, 119-128[Medline] [Order article via Infotrieve] |
| 7. | van Paridon, P. A., Visser, A. J. W. G., and Wirtz, K. W. A. (1987) Biochim. Biophys. Acta 898, 172-180[Medline] [Order article via Infotrieve] |
| 8. |
Dickeson, S. K.,
Lim, C. N.,
Schuyler, G. T.,
Dalton, T. P.,
Helmkamp, G., Jr.,
and Yarbrough, L. R.
(1989)
J. Biol. Chem.
264,
16557-16564 |
| 9. | Geijtenbeek, T. B. H., de Groot, E., van Baal, J., Brunink, F., Westerman, J., Snoek, G. T., and Wirtz, K. W. A. (1994) Biochim. Biophys. Acta 1213, 309-318[Medline] [Order article via Infotrieve] |
| 10. | Dickeson, S. K., Helmkamp, G. M., Jr., and Yarbrough, L. R. (1994) Gene (Amst.) 142, 301-305[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Helmkamp, G. M., Jr. (1990) in Subcellular Biochemistry (Hilderson, H. J., ed), Vol. 16 , pp. 129-174, Plenum Press, New York |
| 12. |
Bankaitis, V. A.,
Malehorn, D. E.,
Emr, S. D.,
and Greene, R.
(1989)
J. Cell Biol.
108,
1271-1281 |
| 13. |
Aitken, J. F.,
van Heusden, G. P. H.,
Temkin, M.,
and Dowhan, W.
(1990)
J. Biol. Chem.
265,
4711-4717 |
| 14. | Bankaitis, V. A., Aitken, J. R., Cleves, A. E., and Dowhan, W. (1990) Nature 347, 561-562[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Wirtz, K. W. A., Helmkamp, G. M., Jr., and Demel, R. A. (1978) in Proteins of the Biological Fluids (Peeters, H., ed) , pp. 25-32, Pergamon Press, Oxford |
| 16. | van Paridon, P. A., Gadella, T. W. J, Somerharju, P. J., and Wirtz, K. W. A. (1987) Biochim. Biophys. Acta 903, 68-77[Medline] [Order article via Infotrieve] |
| 17. | van Paridon, P. A., Somerharju, P., and Wirtz, K. W. A. (1987) Biochem. Soc. Trans. 15, 321-323[Medline] [Order article via Infotrieve] |
| 18. | Berridge, M. J. (1993) Nature 361, 315-325[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract] |
| 20. | Panayotou, G., and Waterfield, M. D. (1993) Bioessays 15, 171-177[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Toker, A., and Cantley, L. C. (1997) Nature 387, 673-676[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Sasakawa, N., Sharif, M., and Hanley, M. R. (1995) Biochem. Pharmacol 150, 137-146 |
| 23. |
Majerus, P. W.,
Connolly, T. M.,
Bansal, V. S.,
Inhorn, R. C.,
Ross, T. S.,
and Lips, D. L.
(1988)
J. Biol. Chem.
263,
3051-3054 |
| 24. |
Alonso, T.,
Morgan, R. O.,
Marvizon, J. C.,
Zarbl, H.,
and Santos, E.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4271-4275 |
| 25. | Valitutti, S., Cucchi, P., Colletta, G., Di Filippo, C., and Corda, D. (1991) Cell. Signal. 3, 321-332[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Iacovelli, L.,
Falasca, M.,
Valitutti, S.,
D'Arcangelo, D.,
and Corda, D.
(1993)
J. Biol. Chem
268,
20402-20407 |
| 27. | Corda, D., and Falasca, M. (1996) Anticancer Res 16, 1341-1350[Medline] [Order article via Infotrieve] |
| 28. | Falasca, M., Carvelli, A., Iurisci, C., Qui, R.-G., Symons, M., and Corda, D. (1997) Mol. Biol. Cell 8, 443-453[Abstract] |
| 29. | Falasca, M., and Corda, D. (1994) Eur. J. Biochem. 221, 383-389[Medline] [Order article via Infotrieve] |
| 30. | Falasca, M., Silletta, M. G., Carvelli, A., Di Francesco, A. L., Fusco, A., Ramakrishna, V., and Corda, D. (1995) Oncogene 10, 2113-2124[Medline] [Order article via Infotrieve] |
| 31. | Metz, S. A. (1986) Biochem. Biophys. Res. Commun. 138, 720-727[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Baran, D. T., and Kelly, M. (1987) Endocrinology 122, 930-934[Abstract] |
| 33. | Thomas, G. M. H., Cunningham, E., Fensome, A., Ball, A., Totty, N. F., Truong, O., Hsuan, J., and Cockcroft, S. (1993) Cell 74, 919-928[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Cunningham, E., Thomas, G. M. H., Ball, A., Hiles, I., and Cockcroft, S. (1995) Curr. Biol. 5, 775-778[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Kular, G., Loubtchenkov, M, Swigart, P., Whatmore, J., Ball, A., Cockcroft, S., and Wetzker, R. (1997) Biochem. J. 325, 299-301 |
| 36. | Hay, J. C., and Martin, F. J. (1993) Nature 366, 572-575[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Fensome, A., Cunningham, E., Prosser, S., Tan, S. K., Swigart, P., Thomas, G., Hsuan, J., and Cockcroft, S. (1996) Curr. Biol. 6, 730-738[CrossRef][Medline] [Order article via Infotrieve] |
| 38. | Ohashi, M., De Vries, K. J., Frank, R., Snoek, G., Bankaitis, V., Wirtz, K., and Huttner, W. B. (1995) Nature 377, 544-547[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Snoek, G. T., de Wit, I. S. C., van Mourik, J. H. G., and Wirtz, K. W. A. (1992) J. Cell. Biochem. 49, 339-348[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | de Vries, K. J., Momchilova-Pankova, A., Snoek, G. T., and Wirtz, K. W. A. (1994) Exp. Cell Res 215, 109-113[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Vieira, J., and Messing, J. (1991) Gene (Amst.) 100, 189-194[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Green, S.,
Issemann, I.,
and Sheer, E.
(1988)
Nucleic Acids Res.
16,
369 |
| 43. | Southern, P. J., and Berg, P. (1982) J. Mol. Appl. Genet. 1, 327-341[Medline] [Order article via Infotrieve] |
| 44. |
Chen, C.,
and Okayama, H.
(1987)
Mol. Cell. Biol.
7,
2745-2752 |
| 45. | Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 96, 634-643 |
| 46. |
Kaufman-Zeh, A.,
Thomas, G. M. H.,
Ball, A.,
Prosser, S.,
Cunningham, E.,
Cockcroft, S.,
and Hsuan, J. J.
(1995)
Science
268,
1188-1190 |
| 47. | Falasca, M., Iurisci, C., Carvelli, A., Sacchetti, A., and Corda, D. (1998) Oncogene 16, 2357-2365[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Van der Bend, R. L., Brunner, J., Jalink, K., van Corven, E. J., Moolenaar, W. H., and van Blitterswijk, W. J. (1992) EMBO J. 11, 2495-2501[Medline] [Order article via Infotrieve] |
| 49. |
Ross, T. S.,
and Majerus, P. W.
(1992)
J. Biol. Chem.
267,
19924-19928 |
| 50. |
Ross, T. S.,
Whiteley, B.,
Graham, R. A.,
and Majerus, P. W.
(1991)
J. Biol. Chem.
266,
9086-9092 |
| 51. | Piomelli, D. (1995) Curr. Biol. 5, 274-280 |
| 52. | Kim, H. K., Kim, J. W., Zilberstein, A., Margolis, B., Kim, J. G., Schlessinger, J., and Rhee, S. G. (1991) Cell 65, 435-441[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Falasca, M,., Marino, M., Carvelli, A., Iurisci, C., Leoni, S., and Corda, D. (1996) Eur. J. Biochem 241, 386-392[Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
S. Mariggio, J. Sebastia, B. M. Filippi, C. Iurisci, C. Volonte, S. Amadio, V. De Falco, M. Santoro, and D. Corda A novel pathway of cell growth regulation mediated by a PLA2{alpha}-derived phosphoinositide metabolite FASEB J, December 1, 2006; 20(14): 2567 - 2569. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Olayioye, S. Vehring, P. Muller, A. Herrmann, J. Schiller, C. Thiele, G. J. Lindeman, J. E. Visvader, and T. Pomorski StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein J. Biol. Chem., July 22, 2005; 280(29): 27436 - 27442. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schenning, C. M. van Tiel, D. van Manen, J. C. Stam, B. M. Gadella, K. W. A. Wirtz, and G. T. Snoek Phosphatidylinositol transfer protein {alpha} regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor J. Lipid Res., August 1, 2004; 45(8): 1555 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. van Tiel, J. Westerman, M. A. Paasman, M. M. Hoebens, K. W. A. Wirtz, and G. T. Snoek The Golgi Localization of Phosphatidylinositol Transfer Protein beta Requires the Protein Kinase C-dependent Phosphorylation of Serine 262 and Is Essential for Maintaining Plasma Membrane Sphingomyelin Levels J. Biol. Chem., June 14, 2002; 277(25): 22447 - 22452. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Alb Jr., S. E. Phillips, K. Rostand, X. Cui, J. Pinxteren, L. Cotlin, T. Manning, S. Guo, J. D. York, H. Sontheimer, et al. Genetic Ablation of Phosphatidylinositol Transfer Protein Function in Murine Embryonic Stem Cells Mol. Biol. Cell, March 1, 2002; 13(3): 739 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. van Tiel, J. Westerman, M. Paasman, K. W. A. Wirtz, and G. T. Snoek The Protein Kinase C-dependent Phosphorylation of Serine 166 Is Controlled by the Phospholipid Species Bound to the Phosphatidylinositol Transfer Protein alpha J. Biol. Chem., July 7, 2000; 275(28): 21532 - 21538. [Abstract] [Full Text] [PDF] |
||||
| |||||||